NEW JERSEY—Clinilabs, an early phase and specialty CRO that provides clinical drug development services to the pharmaceutical industry, has opened a second Phase I unit in Eatontown.
The 50-bed capacity, 15,000-sq.-ft. Specialty Pharma Phase I Unit features semi-private rooms, a large PK sampling facility, a bioanalytic laboratory, pharmacy and exam rooms.
"I am pleased to announce the opening of our new unit in Eatontown, New Jersey," said Dr. Gary Zammit. "This unit allows us to expand our Phase I capacity in two locations, providing first-in-human through end-of-phase II CRO services to our clients. We are now able to enroll larger samples of normal healthy volunteers and patient populations at our two units and at investigator sites worldwide."
Since 2001, Clinilabs has completed clinical trials involving healthy, adult human volunteers and specialty patient populations. The opening of the New Jersey Specialty Pharma Phase I Unit expands services currently offered at the company's 50 bed, Phase I unit in Manhattan, raising total bed capacity to 100.
